



## Stay Informed with the Provider Manual

The Provider Manual is available at [MedMutual.com/Provider](https://www.medmutual.com/provider) > [Provider Manual](#). It is updated quarterly to include the latest policies, procedures and guidelines providers need to work effectively with Medical Mutual.

Sub-sections Revised — Current updates to the Provider Manual include:

- Section 6 – Adjustment and Provider Inquiries Overview:  
The following sections were revised:
  - Provider Website Resources subsection of Provider Inquiries section

## Contact Us

The phone number for our Medical Mutual Provider Contracting team is now 1-800-625-2583. This number is being used in all of our provider contracting regions.

If you do not know who your Provider Contracting Representative is, you can find the information on the contact us page of [MedMutual.com/Provider](https://www.medmutual.com/provider).

# General Information

## Reimbursement Policy

Effective Nov. 1, 2023, Medical Mutual is implementing the PO and PN Modifiers Reimbursement Policy (Policy Number RP-202305).

To view this policy, please visit [MedMutual.com/Provider](https://www.MedMutual.com/Provider) and select Policies and Standards > [Reimbursement Policies](#).

## Important HEDIS Measure and Best Practices for Children and Adolescents on Antipsychotic Medications

Medical Mutual values the care you provide for our members. We are always looking for ways to work with you to improve the health of our members, including children and adolescents on antipsychotic medications.

The following Healthcare Effectiveness Data and Information Set (HEDIS®) measure, along with best practices and CPT® codes, is related to child and adolescent antipsychotic medication use.

### APM (Metabolic Monitoring for Children and Adolescents on Antipsychotics)

This measure evaluates the percentage of children and adolescents 1–17 years of age who had two or more antipsychotic prescriptions and who had annual metabolic testing performed.

Three rates are reported:

1. The percentage of children and adolescents on antipsychotics who received blood glucose testing.
2. The percentage of children and adolescents on antipsychotics who received cholesterol testing.
3. The percentage of children and adolescents on antipsychotics who received blood glucose and cholesterol testing.

The APM measure does not apply to members in hospice.

## Best Practices

- Complete a past family medical history to evaluate for any conditions that could raise the risk of complications from antipsychotic medications (e.g., tardive dyskinesia, diabetes, hypercholesterolemia, and cataracts).
- Assess health complications such as weight gain and diabetes, which can lead to serious metabolic health complications due to medication usage.
- Obtain a baseline and annual body mass index.
- Monitor renal and liver function as these drugs are metabolized through the kidneys and liver. Annual monitoring of at least **one test for blood glucose or HbA1c, and one test for cholesterol**.
- Before starting an antipsychotic medication, perform an Abnormal Involuntary Movement Scale to assess patients for tardive dyskinesia and monitor every 6 months both during medication use and while tapering doses.
- When prescribing antipsychotics, consider “start low and go slow” to find the most effective dosage for the patient and reduce unnecessary side effects.
- Taper antipsychotic medications when stopping as it may cause a relapse.
- Educate the patient and caregivers about common side effects such as increased blood pressure, changes in weight, anxiety, agitation, and insomnia.

## Coding Instructions

Use CPT® codes to close care gaps.

- Cholesterol Lab Test Codes
  - CPT: 80061, 82465, 83700, 83701, 83704, 83718, 83721, 83722, 84478
  - CPT-II: 3048F, 3049F, 3050F
- Glucose Lab Test Codes
  - CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951
- HbA1c Lab Test Codes
  - CPT: 83036, 83037
  - CPT-II: 3044F, 3046F, 3051F, 3052F

Codes and results can be accepted as supplemental data. Contact your Medical Mutual provider representative to discuss data exchange opportunities.



## Primary Care Providers (PCPs)

PCPs can help our members by:

- Establishing a baseline and monitoring blood glucose and cholesterol levels every year to manage side effects.
- Testing blood glucose and cholesterol at a member's annual checkup or school physical to reduce additional visits.
- Encouraging shared decision-making by educating members and caregivers about the:
  - Increased risk of metabolic health complications from antipsychotic medications
  - Importance of screening blood glucose and cholesterol levels

## Behavioral Health Providers

Behavioral health providers can help our members by:

- Ordering blood glucose and cholesterol screening tests for members who do not have regular contact with their PCP.
- Ordering blood glucose and cholesterol screening tests within 1 month of changing a member's medication.

## Behavioral Health Resources

- Behavioral Health Case Management – To connect with a Medical Mutual behavioral health case manager, email [BehavioralHealthDepartment@MedMutual.com](mailto:BehavioralHealthDepartment@MedMutual.com) or call 1-800-258-3175 (TTY:711).
- SonderMind® - SonderMind offers an online library of information about mental and behavioral health. They can also connect members with a local therapist for an in-person or online appointment. Call 1-844-256-9897 (TTY: 711) M-F from 9 a.m. – 8 p.m. E.T. to schedule an appointment or learn more.
- Medical Mutual Coordination of Care Forms - [www.medmutual.com/For-Providers/Continuity-and-Coordination-of-Care.aspx](http://www.medmutual.com/For-Providers/Continuity-and-Coordination-of-Care.aspx).

<https://www.horizonblue.com/providers/resources/hedis-resources/hedis-measurement-year-my-2023-provider-tips-optimizing-hedis-results/metabolic-monitoring-children-and-adolescents-antipsychotics-apm-e>

<https://www.bcbstx.com/docs/provider/tx/clinical/tip-sheets/behaviorial-health/hedis-apm-measure-tipsheet.pdf>

These recommendations are informational only. They are not intended to require a specific course of treatment or take the place of professional medical advice, diagnosis or treatment. Members should make decisions about care with their healthcare providers. Recommended treatment or services may not be covered. Eligibility and coverage depend on the member's specific benefit plan.

None of the information included in this article is intended to be legal advice. It remains the provider's responsibility to ensure that all coding and documentation are done in accordance with applicable state and federal laws and regulations.

CPT Copyright 2023 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

# Medical Policy Updates

## Medical Policy Updates

The Corporate Medical Policies (CMPs) developed, revised or retired between June 1, 2023 and August 31, 2023 are outlined in the following charts. CMPs are regularly reviewed, updated, added or withdrawn, and are subject to change. For a complete list of CMPs, please visit [MedMutual.com/Provider](https://www.MedMutual.com/Provider) and select Policies and Standards > Corporate Medical Policies.

Medical Drug CMPs	
CMP Name	Policy Status
Amondys45	Revised
Antibodies for the treatment of Alzheimer's Disease	Revised
Arcalyst	Revised
Azedra	Revised
Bavencio	Revised
Bevacizumab	Revised
Columvi (glofitamab-bysp)	New
Cosmetic Use policy	Revised
Cyramza	Revised
Elevidys (delandistrogene moxeparvovec-rokl)	New
Elfabrio (pegunigalsidase alfa-iwxj)	New
Enhertu	Revised
Epkinly (epcoritamab-gxbm)	New
Erbitux	Revised
Exondys51	Revised
Gazyva	Revised
General Oncology	Revised
Global PA	Revised
Growth Hormone	Revised
Hemlibra	Revised
Ilumya	Revised
Imfinzi	Revised
Imjudo	Revised
Infugem	New
Jemperli	Revised
Keytruda	Revised
Kyprolis	Revised
Leqvio	Revised

CMP Name	Policy Status
Libtayo	Revised
Lutathera	Revised
Opdivo	New
Palynziq	Revised
Pemetrexed	New
Perjeta	Revised
Praluent	Revised
Qalsody (tofersen)	New
Repatha	Revised
Rituximab_IV	Revised
Roctavian® (valoctocogene roxaparvovec-rvox)	New
Rolvedon	Revised
Ryplazim	Revised
Rystiggo (rozanolixizumab-noli)	New
Siliq	Revised
Skyrizi IV	Revised
Skyrizi SC	Revised
Site of Care	Revised
Soliris	Revised
Spinraza	Revised
Spravato	Revised
Tecentriq	Revised
Trastuzumab_IV	Revised
Ultomiris	Revised
Vectibix	Revised
Viltepso	Revised
Vyjuvek (beremagene geperpavec-svdt)	New
Vyleesi	Revised
Vyondys53	Revised
Vyvgart Hytrulo (efgartigimod alfa; hyaluronidase-qvfc)	New
Vyxeos	Revised
Yervoy	Revised
Yondelis	Revised
Zolgensma	Revised

## Medical CMPs

CMP Name	CMP Number	Policy Status
Carpal Tunnel, Tendon Sheath or Ligament, Tendon and Trigger Point Injection	200218	Revised
Vertebral Artery Angioplasty	202104	Revised
Transcatheter Mitral Valve Repair (TMVr)	202012	Revised
Prolotherapy - Musculoskeletal Conditions	201105	Revised
Next-Generation Sequencing for Detection and Quantification of Lymphoid Cancers	201923	Revised
High-Frequency Chest Wall Oscillation System and Intrapulmonary Percussive - DME	200508	Revised
Noninvasive Rupture of Membranes Testing in Pregnancy	201535	Revised
Peripheral Nerve Stimulation and Electrical Stimulation for Pain and Other Conditions	201004	Revised
Pneumatic Compression Device - Pneumatic Compression of Trunk and Chest	201621	Revised
Vectra DA Blood Test	201504	Revised
Radiofrequency Microtenotomy	2006-D	Revised
Vertebral Axial Decompression (VAX-D)	2005-J	Revised
Functional Electrical Stimulation for Rehabilitation of Paralyzed Lower Extremities	200604	Revised
LLLT for mucositis in cancer of the head and neck	202206	Revised
Spinal Cord Stimulation for Treatment of Chronic Pain	200602	Revised
Vertebral Body Tethering	202013	Revised
Auditory Brainstem Response Testing	200215	Revised
Cosmetic Procedures	201929	Revised
Radiofrequency Treatment Pain	201537	Revised
Percutaneous left atrial appendage closure (LAAC) for non-valvular atrial fibrillation	201718	Revised
Skin Surveillance Technologies	200903	Revised
Pancreatic Islet Cell Transplant	201102	Revised
Nonsurgical Treatment of Obstructive Sleep Apnea: Oral Pressure Therapy	2014-A	Revised
Cryoablation of Solid Tumors	200802	Revised
Thermography	201324	Revised



## Medical CMPs

CMP Name	CMP Number	Policy Status
Microsurgical Treatments for Lymphedema	202011	Revised
Ultrasound Transient Elastography	201935	Revised
Focal Articular Cartilage Defect Treatment Osteochondral Allograft	200613	Revised
Hydrogen Breath Test for Irritable Bowel Syndrome	2015-D	Revised
Tumor Treating Fields	201607	Revised
Allogeneic, xenographic, synthetic, and composite nerve grafts and conduits	2019-F	Revised
Vision Training	201103	Revised
Actigraphy	2018-C	Revised
Non-wearable automatic external defibrillator (AED)	201617	Revised
Contact Lenses	200131	Revised
Infertility Services (FEHB)	202306-CSTM	Revised
Intrastromal Corneal Ring Segments for the Treatment of Keratoconus	200504	Revised
Gender Affirming Surgery (FEHB)	201609-CSTM	Revised
Sacral Nerve Stimulation	200616	Retired
Fractional flow reserve derived from computed tomography (FFRCT)	201931	Retired
Corneal Cross Linking	201946	Retired

For a list of services requiring prior approval or considered investigational, please visit [MedMutual.com/Provider](https://www.MedMutual.com/Provider) and select Policies and Standards > [Prior Approval & Investigational Services](#).

All rights in the product names of all third-party products appearing here, whether appearing with the trademark symbol, belong exclusively to their respective owners.

# Pharmacy

## Earn Continuing Education (CE) Credits: Incorporating Antibiotic Stewardship in Your Practice

The Centers for Disease Control and Prevention (CDC) estimates approximately 47 million courses of antibiotics are prescribed unnecessarily each year.<sup>1</sup>

Two important measures monitored by the National Committee for Quality Assurance (NCQA) related to antibiotic use are:

- Appropriate Treatment for Upper Respiratory Infections (URI)
- Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)

Antibiotic stewardship, the effort to measure and improve how antibiotics are prescribed, can help you stay diligent and ensure appropriate antibiotic use with your patients.

### Earning CE Credits

To help with this effort, the CDC is offering an online training course on antibiotic stewardship available at [www.cdc.gov/antibiotic-use/training/continuing-education.html](http://www.cdc.gov/antibiotic-use/training/continuing-education.html). The course includes multiple modules with free continuing education (CE) credits that can be taken in any order.

Course objectives:

- Describing the role of the healthcare team in antibiotic stewardship
- Updating healthcare professionals on current antimicrobial resistance threats
- Encouraging open discussion among physicians and patients about appropriate antibiotic prescribing

If you need help starting an antibiotic stewardship program, or are looking to assess if your current program is working, here are some tools from the CDC you can use.

- The Core Elements of Hospital Antibiotic Stewardship Programs [www.cdc.gov/antibiotic-use/healthcare/pdfs/assessment-tool-P.pdf](http://www.cdc.gov/antibiotic-use/healthcare/pdfs/assessment-tool-P.pdf)
- The Core Elements of Outpatient Antibiotic Stewardship [www.cdc.gov/antibiotic-use/community/pdfs/16\\_268900-A\\_CoreElementsOutpatient\\_check\\_1\\_508.pdf](http://www.cdc.gov/antibiotic-use/community/pdfs/16_268900-A_CoreElementsOutpatient_check_1_508.pdf)

### References and Resources

1. Antibiotics Aren't Always the Answer. Centers for Disease Control and Prevention. [www.cdc.gov/antibiotic-use/pdfs/AntibioticsArentAlwaysTheAnswer-H.pdf](http://www.cdc.gov/antibiotic-use/pdfs/AntibioticsArentAlwaysTheAnswer-H.pdf)

These recommendations are informational only. They are not intended to require a specific course of treatment or take the place of professional medical advice, diagnosis or treatment. Members should make decisions about care with their healthcare providers. Recommended treatment or services may not be covered. Eligibility and coverage depend on the member's specific benefit plan.



## Pharmacy Prior Approval Requirements

Medical Mutual requires prior approval for the following drugs regardless of whether they are covered under the medical or pharmacy benefits:

- All new specialty drugs
- All new drugs with significant safety, clinical or potential abuse or diversion concerns

This requirement is intended to ensure medications are used safely and will be effective for members. The prior approval criteria for these drugs are detailed in the Global PA/New Drug Prior Approval policy available at [Medmutual.com/Provider](https://www.medmutual.com/Provider) on the following pages:

**For drugs covered under the medical benefit:** Select Policies and Standards > [Corporate Medical Policies](#).

This page also includes all current Corporate Medical Policies and information about our prior approval services and [Magellan Rx's secure provider portal](#), a web-based tool at [www1.magellanrx.com](http://www1.magellanrx.com) that providers can use to manage prior approval requests for medications.

**For drugs covered under the pharmacy benefit:** Select Policies and Standards > Prescription Drug Resources, then click the link under [Prior Authorization](#) to see the list. This page also includes information about our other coverage management programs (e.g., step therapy, quantity limits) and formularies, as well as a link to the ExpressPAth tool.



2060 East Ninth Street  
Cleveland, OH 44115-1355

© 2023 Medical Mutual of Ohio  
X9309-PRV R10/23

# Mutual News

Third Quarter, 2023

## Inside This Issue

Provider Manual Updates .....	1
General Information .....	2
Medical Policy Updates .....	7
Pharmacy .....	11

## Receive this Newsletter in Your Email!

Enroll or login to Availity at [Availity.com/medicalmutual](https://www.availity.com/medicalmutual), locate the Medical Mutual payer space, go to the Applications Tab and input the applicable email address.

---

Medical Mutual, Medical Mutual of Ohio and the Medical Mutual logo are registered trademarks of Medical Mutual of Ohio. Other product names, brands and any other trademarks listed or referred to in this publication are the property of their respective trademark holders. These trademark holders are not affiliated with Medical Mutual of Ohio. Such trademark holders do not sponsor or endorse our materials.

This material is considered part of the Provider Manual for Medical Mutual of Ohio® and its subsidiaries. Mutual News and Mutual News Bulletin are published for network providers serving Medical Mutual. To contact us or for more information, visit [MedMutual.com/Provider](https://www.MedMutual.com/Provider).